对一个具有新型EFEMP1突变(c.1313, p.Tyr438Cys)的少年开角型青光眼家系进行长期随访。

IF 3.2 Q2 Medicine
Brian P Young, Angela W Nyunt, Molly A Clymer, Mallory R Tollefson, Ben R Roos, Michael J Schnieders, Alan L Robin, John H Fingert
{"title":"对一个具有新型EFEMP1突变(c.1313, p.Tyr438Cys)的少年开角型青光眼家系进行长期随访。","authors":"Brian P Young, Angela W Nyunt, Molly A Clymer, Mallory R Tollefson, Ben R Roos, Michael J Schnieders, Alan L Robin, John H Fingert","doi":"10.1016/j.ogla.2025.08.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Determine the genetic cause of glaucoma in a juvenile open-angle glaucoma (JOAG) pedigree of European ancestry.</p><p><strong>Design: </strong>Case series or pedigree analysis PARTICIPANTS: A three-generation JOAG pedigree METHODS: We obtained clinical data and tested DNA for mutations in known JOAG-causing genes with Sanger sequencing for MYOC and whole exome sequencing for EFEMP1. We assessed identified mutations for pathogenicity by (1) frequency in control databases; (2) mutation analysis algorithms; (3) homology analyses; and (4) structural modeling of mutational effects on encoded proteins.</p><p><strong>Main outcome measures: </strong>Detection of a mutation that is coinherited with glaucoma in the JOAG pedigree. Secondary measures include descriptions of glaucoma phenotype (age at presentation, maximum intraocular pressure [IOP], progression rate, and response to therapy).</p><p><strong>Results: </strong>Clinical data from an average follow-up of 11.5 ± 7.05 years were available from four family members with JOAG. Members of this pedigree had a mean age of diagnosis of 32.5 ± 8.6 years (range 25-43 years) and a mean maximum treated IOP of 32.3 ± 12.0 (range 16-50) mmHg. Family members had visual field progression ranging from -0.25 to -1.1 dB/year and required an average of 1.8 ± 1.0 incisional glaucoma surgeries per eye for IOP control. No MYOC mutations were detected. A heterozygous missense mutation (c.1313A>G, p.Tyr438Cys) was detected in the EFEMP1 gene in all four family members with JOAG and is absent from control subjects. The p.Tyr438Cys mutation altered a highly conserved amino acid and was predicted to be pathogenic by 6 mutation analysis algorithms. Modeling of the p.Tyr438Cys mutation indicated it causes structural changes to EFEMP1 protein that are likely detrimental to its function.</p><p><strong>Conclusions: </strong>This study identifies a novel mutation, p.Tyr438Cys, as the first known glaucoma-causing EFEMP1 mutation in a JOAG pedigree of European ancestry. Patients with the EFEMP1 mutation p.Tyr438Cys have an early-onset severe glaucoma phenotype with high maximum IOPs that require surgical interventions and may have rapid progression. These data underscore the severity of this type of JOAG and the need for further research into its pathogenic mechanisms and therapeutic management.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":56368,"journal":{"name":"Ophthalmology. Glaucoma","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-Term Follow-Up on a Juvenile Open-Angle Glaucoma Pedigree with a Novel EFEMP1 Mutation (c.1313, p.Tyr438Cys).\",\"authors\":\"Brian P Young, Angela W Nyunt, Molly A Clymer, Mallory R Tollefson, Ben R Roos, Michael J Schnieders, Alan L Robin, John H Fingert\",\"doi\":\"10.1016/j.ogla.2025.08.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Determine the genetic cause of glaucoma in a juvenile open-angle glaucoma (JOAG) pedigree of European ancestry.</p><p><strong>Design: </strong>Case series or pedigree analysis PARTICIPANTS: A three-generation JOAG pedigree METHODS: We obtained clinical data and tested DNA for mutations in known JOAG-causing genes with Sanger sequencing for MYOC and whole exome sequencing for EFEMP1. We assessed identified mutations for pathogenicity by (1) frequency in control databases; (2) mutation analysis algorithms; (3) homology analyses; and (4) structural modeling of mutational effects on encoded proteins.</p><p><strong>Main outcome measures: </strong>Detection of a mutation that is coinherited with glaucoma in the JOAG pedigree. Secondary measures include descriptions of glaucoma phenotype (age at presentation, maximum intraocular pressure [IOP], progression rate, and response to therapy).</p><p><strong>Results: </strong>Clinical data from an average follow-up of 11.5 ± 7.05 years were available from four family members with JOAG. Members of this pedigree had a mean age of diagnosis of 32.5 ± 8.6 years (range 25-43 years) and a mean maximum treated IOP of 32.3 ± 12.0 (range 16-50) mmHg. Family members had visual field progression ranging from -0.25 to -1.1 dB/year and required an average of 1.8 ± 1.0 incisional glaucoma surgeries per eye for IOP control. No MYOC mutations were detected. A heterozygous missense mutation (c.1313A>G, p.Tyr438Cys) was detected in the EFEMP1 gene in all four family members with JOAG and is absent from control subjects. The p.Tyr438Cys mutation altered a highly conserved amino acid and was predicted to be pathogenic by 6 mutation analysis algorithms. Modeling of the p.Tyr438Cys mutation indicated it causes structural changes to EFEMP1 protein that are likely detrimental to its function.</p><p><strong>Conclusions: </strong>This study identifies a novel mutation, p.Tyr438Cys, as the first known glaucoma-causing EFEMP1 mutation in a JOAG pedigree of European ancestry. Patients with the EFEMP1 mutation p.Tyr438Cys have an early-onset severe glaucoma phenotype with high maximum IOPs that require surgical interventions and may have rapid progression. These data underscore the severity of this type of JOAG and the need for further research into its pathogenic mechanisms and therapeutic management.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>\",\"PeriodicalId\":56368,\"journal\":{\"name\":\"Ophthalmology. Glaucoma\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Glaucoma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ogla.2025.08.003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Glaucoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ogla.2025.08.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:确定欧洲血统的JOAG家系青光眼的遗传原因。方法:我们获得临床数据,并使用Sanger测序(MYOC)和EFEMP1全外显子组测序(EFEMP1)检测已知JOAG致病基因突变的DNA。我们通过对照数据库中的频率评估已鉴定突变的致病性;2)突变分析算法;3)同源性分析;4)编码蛋白突变效应的结构建模。主要结果测量:检测JOAG家系中与青光眼共同遗传的突变。次要指标包括青光眼表型描述(发病年龄、最大眼压(IOP)、进展率和对治疗的反应)。结果:4名患有JOAG的家庭成员平均随访11.5±7.05年,获得临床资料。该家族成员的平均诊断年龄为32.5±8.6岁(范围25至43岁),平均最大治疗IOP为32.3±12.0(范围20至50)mm Hg。家族成员的视野进展范围为-0.25至-1.1 dB /年,平均每只眼需要1.8±1.0切口青光眼手术来控制IOP。未检测到MYOC突变。四名JOAG家族成员的EFEMP1基因均存在杂合错义突变(c.1313A>G, p.Tyr438Cys),而对照组不存在该突变。p.Tyr438Cys突变改变了一个高度保守的氨基酸,通过6种突变分析算法预测该突变具有致病性。p.Tyr438Cys突变的建模表明,它会导致EFEMP1蛋白的结构变化,这可能对其功能有害。结论:本研究确定了一种新的突变p.Tyr438Cys,作为欧洲血统JOAG家系中第一个已知的导致青光眼的EFEMP1突变。EFEMP1突变p.Tyr438Cys的患者具有早发性严重青光眼表型,最大IOPs高,需要手术干预,并且可能有快速进展。这些数据强调了这种类型JOAG的严重性,以及对其致病机制和治疗管理进行进一步研究的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-Term Follow-Up on a Juvenile Open-Angle Glaucoma Pedigree with a Novel EFEMP1 Mutation (c.1313, p.Tyr438Cys).

Purpose: Determine the genetic cause of glaucoma in a juvenile open-angle glaucoma (JOAG) pedigree of European ancestry.

Design: Case series or pedigree analysis PARTICIPANTS: A three-generation JOAG pedigree METHODS: We obtained clinical data and tested DNA for mutations in known JOAG-causing genes with Sanger sequencing for MYOC and whole exome sequencing for EFEMP1. We assessed identified mutations for pathogenicity by (1) frequency in control databases; (2) mutation analysis algorithms; (3) homology analyses; and (4) structural modeling of mutational effects on encoded proteins.

Main outcome measures: Detection of a mutation that is coinherited with glaucoma in the JOAG pedigree. Secondary measures include descriptions of glaucoma phenotype (age at presentation, maximum intraocular pressure [IOP], progression rate, and response to therapy).

Results: Clinical data from an average follow-up of 11.5 ± 7.05 years were available from four family members with JOAG. Members of this pedigree had a mean age of diagnosis of 32.5 ± 8.6 years (range 25-43 years) and a mean maximum treated IOP of 32.3 ± 12.0 (range 16-50) mmHg. Family members had visual field progression ranging from -0.25 to -1.1 dB/year and required an average of 1.8 ± 1.0 incisional glaucoma surgeries per eye for IOP control. No MYOC mutations were detected. A heterozygous missense mutation (c.1313A>G, p.Tyr438Cys) was detected in the EFEMP1 gene in all four family members with JOAG and is absent from control subjects. The p.Tyr438Cys mutation altered a highly conserved amino acid and was predicted to be pathogenic by 6 mutation analysis algorithms. Modeling of the p.Tyr438Cys mutation indicated it causes structural changes to EFEMP1 protein that are likely detrimental to its function.

Conclusions: This study identifies a novel mutation, p.Tyr438Cys, as the first known glaucoma-causing EFEMP1 mutation in a JOAG pedigree of European ancestry. Patients with the EFEMP1 mutation p.Tyr438Cys have an early-onset severe glaucoma phenotype with high maximum IOPs that require surgical interventions and may have rapid progression. These data underscore the severity of this type of JOAG and the need for further research into its pathogenic mechanisms and therapeutic management.

Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Ophthalmology. Glaucoma
Ophthalmology. Glaucoma Medicine-Medicine (all)
CiteScore
4.20
自引率
0.00%
发文量
140
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信